Skip to content

Inspection Record

Biomylz Private Limited — FDA 483 Findings

US FDAInspected 2026-02-09Published 2026-10-22 6 findingsEquipment and facilityQuality unit oversightLaboratory and QC controlsDeviation, CAPA, and investigation

Inspectors Alan A. RiveraThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

2Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not fully followed.

3Laboratory and QC controls

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.

4Deviation, CAPA, and investigation

Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed.

5Laboratory and QC controls

Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.

6Equipment and facility

Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-22. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Biomylz Private Limited findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.